Nexalis Therapeutics Limited (ASX:NX1)

Australia · Delayed Price · Currency is AUD

0.0090

-0.0010 (-10.00%)

At close: Sep 18, 2026

Market Cap	2.53M -67.1%
Revenue (ttm)	1.07M +28.0%
Net Income	-2.06M
EPS	-0.01
Shares Out	253.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,461
Open	0.0090
Previous Close	0.0100
Day's Range	0.0090 - 0.0090
52-Week Range	0.0070 - 0.0360
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 1, 2026

About Nexalis Therapeutics

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limit... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol NX1

Full Company Profile

Financial Performance

In 2025, Nexalis Therapeutics's revenue was 986,434, an increase of 145.50% compared to the previous year's 401,811. Losses were -1.62 million, 33.9% more than in 2024.

Financial Statements